About the testing
The COVID-19 pandemic has an unprecedented impact on practically all aspects of our lives. Due to its variability and its ability to adapt to new environments, it globally continues its growing tendency. Researchers are working at an extraordinary pace to understand biological virus, while investigating potential therapeutics and vaccine treatments.
For screening and suspicious testing of individuals with some suspected SARS-CoV-2 infection in conjunction with clinical manifestations we now offer RAPID-VIDITEST SARS-CoV-2 rapid non-invasive tests. These tests are designed to determine the SARS-CoV-2 virus antigen, as well as the appropriate antibodies to test the post-vaccination and post-infection conditions of individuals.
The qualitative detection
- - from swabs from the nasal cavity
- - from oral swabs
- - from nasopharyngeal swabs
If a person has been infected with the SARS-CoV-2 virus, three types of antibodies to the virus begin to form in the body - IgA, IgM and IgG. The human body usually begins to produce IgA and IgM antibodies after three to five days of virus infection. IgA antibodies indicate an infection or a termination phase. Subsequently, after two to three weeks, IgG-type antibodies also develop with a delay and the IgM level subsequently decreases. However, IgG antibodies persist for months.
We offer rapid immunochromatic tests for the qualitative determination of specific antibodies in patients previously exposed to the SARS-CoV-2 virus, including recently infected patients and patients with a mild response. RAPID-VIDITEST anti-SARS-CoV-2 IgG / IgM. The test tells you if the patient has had an infection in the past and if they have protective IgG memory antibodies in their blood.
For the quantitative detection of specific IgG, IgA and IgM antibodies against SARS-CoV-2 we provide our precise immunological kits using the principles of ELISA - ELISA-VIDITEST SARS-CoV-2 IgA, IgG, IgM and disposable cassette kits - MONO-VIDITEST SARS-CoV-2 IgA, IgG, IgM.
The determination of specific
- - RAPID-VIDITEST
- - ELISA-VIDITEST
- - MONO-VIDITEST
About the virus
SARS-CoV-2 belongs to the genus of coronaviruses β. It consists of 4 major structural proteins: surface (S), envelope (E), transmembrane (M) glycoprotein, and internal phosphorylated nucleocapsid protein (N). The virus genome further encodes a total of 16 non-structural proteins (nsp1-nsp16) and accessory proteins. However, the main virulence factor is mainly the surface S (spike) glycoprotein, which consists of 2 subunits S1 and S2. The first subunit (S1) serves to bind the virion to cellular receptors, while the second subunit (S2) is involved in the fusion of the virus with the cell membrane. Surface Spike protein induces the production of specific neutralizing antibodies.
About the infection
New coronavirus SARS-CoV-2 causes an acute respiratory infectious disease in humans called COVID-19.
The infection is transmitted mainly by the droplet route and its incubation period is reported to be between 2 and 14 days. In most infected individuals, the disease is mild. However, some patients may experience severe pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and multiorgan failure. The main symptoms of the infection include fever, irritating cough, general tiredness, muscle aches or shortness of breath. In a few cases, a stuffy nose, runny nose, sore throat, myalgia and diarrhea occur, especially in young children.